Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Novartis
Chinese Patent Office
Baxter
Harvard Business School
Julphar
Healthtrust
Boehringer Ingelheim
Citi
McKinsey
AstraZeneca

Generated: October 23, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,251,091

« Back to Dashboard

Which drugs does patent 6,251,091 protect, and when does it expire?


Patent 6,251,091 protects SUMAVEL DOSEPRO and is included in one NDA.

This patent has twenty-two patent family members in fifteen countries.

Summary for Patent: 6,251,091

Title: Needleless injector drug capsule and filling method
Abstract:A needleless injector capsule for a liquid medicament has a filling adaptor removably, and preferably frangibly, attached thereto. The capsule has a chamber for receiving injectate, the chamber being provided with an injection orifice, and having a piston located for movement therein. The adaptor has a bore which communicates with the capsule chamber via the injection orifice. The capsule is filled by introducing injectate into the capsule chamber through the injection orifice and excess injectate into bore of the adaptor, and closing the bore of the adaptor to the exterior by a sealing means, leaving the bore partly filled with excess injectate.
Inventor(s): Weston; Terence Edward (Eye, GB)
Assignee: Weston Medical Limited (Eye, GB)
Application Number:09/091,320
Patent Claim Types:
see list of patent claims
Dosage form; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Endo Ventures Ltd
SUMAVEL DOSEPRO
sumatriptan succinate
INJECTABLE;SUBCUTANEOUS022239-001Jul 15, 2009BXRXYesYes► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 6,251,091

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom9525757Dec 16, 1995
PCT Information
PCT FiledDecember 09, 1996PCT Application Number:PCT/GB96/03017
PCT Publication Date:June 26, 1997PCT Publication Number: WO97/22375

International Patent Family for Patent: 6,251,091

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria204772► Subscribe
Australia1102397► Subscribe
Australia4935800► Subscribe
Brazil9612003► Subscribe
Canada2240581► Subscribe
Germany69614881► Subscribe
Denmark0876175► Subscribe
European Patent Office0876175► Subscribe
European Patent Office1097727► Subscribe
European Patent Office1180046► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
Cantor Fitzgerald
Chinese Patent Office
McKinsey
Colorcon
Cipla
Covington
Novartis
QuintilesIMS
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot